ANCA vasculitis is a rare autoimmune disease characterized by inflammation of small to medium-sized blood vessels due to anti-neutrophil cytoplasmic antibodies (ANCA). Tayeba Roper et al., 2024, reported that the diseases accounts for around 13-20 cases per million population annually. The ANCA vasculitis pipeline analysis by Expert Market Research highlights a growing focus on targeted biologics and immunosuppressive therapies. Advancements in diagnostic tools and clinical trials for novel monoclonal antibodies are driving market growth. Rising awareness and improved treatment access are expected to accelerate the development of ANCA vasculitis therapeutics in the coming years.
Major companies involved in the ANCA vasculitis pipeline analysis include Amgen, NovelMed Therapeutics, and others.
Leading drugs currently in the pipeline include NM8074, FT819, and ADI-001, among others.
The pipeline for ANCA vasculitis is expanding with increased clinical trials of biologics, rising investment in novel immunotherapies, and growing focus on B-cell targeted therapies for sustained disease control.
The ANCA Vasculitis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into ANCA vasculitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for ANCA vasculitis. The ANCA vasculitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The ANCA vasculitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with ANCA vasculitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to ANCA vasculitis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Anti-neutrophil cytoplasmic antibody (ANCA) vasculitis is a rare autoimmune disorder that leads to inflammation of small to medium-sized blood vessels. It occurs when the immune system mistakenly produces antibodies against neutrophils, a type of white blood cell. These antibodies activate neutrophils, causing them to damage blood vessels, which may affect organs like kidneys and lungs.
ANCA vasculitis treatment involves corticosteroids and immunosuppressive drugs such as cyclophosphamide or Rituximab to reduce inflammation and prevent organ damage. Early diagnosis and appropriate therapy are essential to improve outcomes. In June 2024, the U.S. Food and Drug Administration (FDA) approved a Phase II clinical trial for Ruxoprubart in ANCA vasculitis. This investigational therapy, developed by NovelMed, targets the alternative complement pathway to offer enhanced efficacy and safety as an adjunct to standard care.
According to Tayeba Roper et al., 2024, ANCA-associated vasculitis (AAV) affects 13-20 people per million each year in Europe, North America, and Australasia. The global prevalence ranges from 30 to 218 per million. Granulomatosis with polyangiitis and PR3-ANCA are more common in Europe and North America, while microscopic polyangiitis and MPO-ANCA are more frequent in Asia. AAV is slightly more common in males and peaks in people aged 65 to 74 years.
This section of the report covers the analysis of ANCA vasculitis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total ANCA vasculitis clinical trials, with 34%. It is followed by phase II at 28%, and phase III at around 15%. Early phase I accounts for 11%, while phase IV comprises 10%. This robust clinical pipeline across multiple phases reflects strong research momentum, supporting future advancements and growth in the ANCA vasculitis treatment landscape.
The drug molecule categories covered under the ANCA vasculitis pipeline analysis include small molecules, monoclonal antibodies, peptides, gene therapies, and cell therapies. The ANCA vasculitis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ANCA vasculitis.
Complement inhibitor-based therapies are gaining attention in the ANCA-associated vasculitis pipeline. For instance, avacopan, a C5a receptor antagonist, has shown promise in combination with rituximab for inducing and sustaining remission. This approach may offer a steroid-sparing alternative with reduced relapse rates and improved renal outcomes, addressing the limitations of traditional glucocorticoid-based regimens.
The EMR report for the ANCA vasculitis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed ANCA vasculitis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in ANCA vasculitis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for ANCA vasculitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of ANCA vasculitis drug candidates.
NM8074, developed by NovelMed Therapeutics, is a humanized monoclonal antibody targeting factor Bb to inhibit the alternative complement pathway. The ongoing Phase II trial is evaluating its safety, tolerability, and efficacy in patients with ANCA-associated vasculitis when combined with standard therapies like cyclophosphamide or rituximab and corticosteroids. The study aims to demonstrate targeted remission potential.
FT819, developed by Fate Therapeutics, is an off-the-shelf, CD19-targeted, 1XX CAR T-cell therapy currently undergoing a Phase 1 trial. The study is evaluating its safety, pharmacokinetics, and B-cell targeting activity in ANCA-associated vasculitis. FT819 is being administered as a single dose with or without conditioning regimens, aiming to address relapsed or refractory autoimmune conditions.
ADI-001, developed by Adicet Therapeutics, is an investigational allogeneic gamma delta CAR T cell therapy targeting CD20. This Phase 1 study is evaluating its safety and efficacy in treating autoimmune diseases, including ANCA-associated vasculitis. The trial aims to identify the optimal dose while assessing tolerability. Enrollment for AAV patients is expected to begin in the second half of 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The ANCA Vasculitis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for ANCA vasculitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into ANCA vasculitis collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share